Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 12, Issue 3, 2014

Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits suc Read More

Despite the common use of antidepressant drugs for the treatment of various psychiatric illnesses, selection of initial antidepressant therapy and subsequent drug modification strategies continue to be largely based on trial and error. There are no biomarkers that can objectively guide dose and treatment selection or alteration. The approach for antidepressant therapy management is even more concerning when we consid Read More

Assessment of added value of stratified medicine (SM) interventions is complex and depends on many factors including the performance of the diagnostic test and the utility of the test for informing patient management. Modelling studies based on decision analysis is a well-recognized method used for health technology assessments (HTA’s) of health care interventions to analyse the consequences of decisions that are Read More

Acute myocardial infarction (AMI) is a common and complex disease; pathogenesis of AMI is not completely understood and genetic, clinical and phenotypic variables are involved in the disease’s history. The aim of this paper was to assess: 1) the predictive capacity of Artificial Neural Networks (ANNs) in consistently distinguishing the two different conditions (AMI or control). 2) the identification of the variables with the Read More

Pharmacogenomics (PGx) knowledge and practical applications in academic medicine and public health are expanding worldwide. In the past ten years, genotyping technologies have emerged in Jordan through the establishment of several research centers and university departments. The goals of this study were to assess the extensiveness, depth, and perceived importance of PGx instruction, in addition to the knowledge a Read More

The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therape Read More